NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 23 04:00PM ET
33.23
Dollar change
+5.88
Percentage change
21.50
%
IndexRUT P/E- EPS (ttm)-0.31 Insider Own84.93% Shs Outstand737.63M Perf Week34.97%
Market Cap24.51B Forward P/E- EPS next Y-0.60 Insider Trans0.00% Shs Float111.14M Perf Month60.61%
Income-221.31M PEG- EPS next Q-0.09 Inst Own12.61% Short Float21.38% Perf Quarter41.28%
Sales0.00M P/S- EPS this Y-37.58% Inst Trans9.99% Short Ratio7.73 Perf Half Y56.67%
Book/sh0.53 P/B63.05 EPS next Y-40.72% ROA-69.32% Short Interest23.77M Perf Year849.43%
Cash/sh0.56 P/C59.40 EPS next 5Y-28.25% ROE-94.89% 52W Range2.10 - 33.89 Perf YTD86.21%
Dividend Est.- P/FCF- EPS past 5Y-10.52% ROI-56.43% 52W High-1.95% Beta-1.16
Dividend TTM- Quick Ratio10.15 Sales past 5Y-8.94% Gross Margin- 52W Low1482.38% ATR (14)2.42
Dividend Ex-Date- Current Ratio10.15 EPS Y/Y TTM80.00% Oper. Margin- RSI (14)75.54 Volatility10.31% 11.05%
Employees159 Debt/Eq0.02 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price35.25
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-59.00% Payout- Rel Volume4.02 Prev Close27.35
Sales Surprise- EPS Surprise2.20% Sales Q/Q- EarningsFeb 24 BMO Avg Volume3.07M Price33.23
SMA2052.63% SMA5061.21% SMA20081.35% Trades Volume11,796,506 Change21.50%
Date Action Analyst Rating Change Price Target Change
Mar-26-25Upgrade Citigroup Neutral → Buy $23 → $35
Mar-21-25Initiated Cantor Fitzgerald Overweight
Mar-12-25Initiated Evercore ISI Outperform $30
Feb-28-25Initiated Goldman Buy $42
Jan-08-25Initiated Truist Buy $35
Dec-11-24Initiated Wells Fargo Overweight $30
Dec-06-24Initiated Jefferies Buy $31
Nov-04-24Initiated JMP Securities Mkt Outperform $32
Sep-27-24Downgrade Citigroup Buy → Neutral $19 → $23
Aug-12-24Initiated H.C. Wainwright Buy $16
Today 08:00AM
Apr-23-25 06:13PM
04:10PM
04:05PM
03:47PM
06:15AM Loading…
06:15AM
05:45AM
Apr-22-25 07:32AM
Apr-20-25 10:15AM
Apr-19-25 07:40AM
Apr-15-25 12:40AM
Apr-14-25 09:08AM
05:57AM
Apr-12-25 06:45PM
02:45PM
12:35PM Loading…
12:35PM
02:10AM
Apr-11-25 12:15PM
12:10PM
06:46AM
Apr-10-25 04:36PM
Apr-06-25 07:02AM
Apr-04-25 04:15PM
Apr-03-25 11:30AM
09:45AM
Mar-31-25 03:25PM
04:53AM
Mar-30-25 11:35AM
Mar-28-25 11:30AM
07:30AM
05:21PM Loading…
Mar-26-25 05:21PM
09:28AM
Mar-23-25 05:49AM
Mar-21-25 04:15PM
Mar-19-25 10:11AM
09:00AM
Mar-17-25 04:24PM
Mar-14-25 04:15PM
08:13AM
Mar-13-25 07:04PM
07:30AM
Mar-08-25 06:39PM
Mar-04-25 01:00AM
Feb-27-25 01:14PM
Feb-25-25 11:17AM
03:56AM
02:01AM
Feb-24-25 12:52PM
12:43PM
10:13AM
06:05AM
06:00AM
Feb-18-25 09:00AM
Feb-17-25 04:32AM
Feb-14-25 04:15PM
Feb-09-25 06:15AM
Feb-08-25 09:01AM
08:50AM
Feb-07-25 05:30AM
Feb-03-25 01:11PM
Jan-30-25 09:15AM
Jan-29-25 03:58PM
Jan-26-25 02:40AM
Jan-23-25 05:47AM
Jan-21-25 12:06PM
Jan-20-25 07:00PM
Jan-18-25 05:52PM
Jan-16-25 04:15PM
Jan-15-25 09:35AM
Jan-07-25 07:00AM
Jan-04-25 06:48AM
Jan-01-25 12:45PM
Dec-29-24 06:47AM
Dec-23-24 10:36AM
Dec-20-24 10:21AM
06:30AM
04:50AM
Dec-18-24 05:44AM
Dec-15-24 07:37AM
Dec-14-24 04:00PM
Dec-13-24 04:15PM
Dec-06-24 07:09PM
Dec-02-24 04:22AM
Nov-30-24 06:05AM
Nov-26-24 04:15PM
Nov-23-24 06:30AM
Nov-21-24 04:15PM
Nov-20-24 08:27AM
Nov-14-24 04:54PM
Nov-10-24 06:26PM
Nov-08-24 07:00AM
Nov-04-24 06:56PM
02:14PM
01:43PM
Nov-03-24 06:41AM
Oct-31-24 08:29AM
07:01AM
01:06AM
Oct-30-24 07:00AM
Oct-27-24 02:29PM
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.